Basic and clinical studies on biapenem in genito-urinary infections

Toyohiko Watanabe, T. Takenaka, T. Hayashi, K. Hata, N. Ono, H. Kumon, H. Ohmori, K. Kinugawa, H. Tanaka, M. Takada, K. Nanba, K. Takeda, T. Asahi, S. Uno, T. Jousen

Research output: Contribution to journalArticle

Abstract

We studied the antibacterial activity and clinical efficacy of biapenem (BIPM), a new carbapenem antibiotic, in the genito-urinary infections. 1) Antibacterial activity: We measured the MICs of BIPM against clinical isolates (210 strains of 14 species) from urinary tract infections, and compared them with those of imipenem (IPM), ceftazidime (CAZ), latamoxef (LMOX)and cefoperazone (CPZ). In general, antibacterial activities of BIPM were almost equal to those of IPM, but superior to those of other control drugs. 2) Clinical efficacy: According to the criteria of Japanese UTI committee, the overall clinical efficacy rate was 73.9% (17/23) for chronic complicated UTI. Bacteriologically, 30 of 35 strains (85.7%) were eradicated. 3) Side effect: Clinical side effects and abnormal laboratory changes were not observed in any cases.

Original languageEnglish
Pages (from-to)486-496
Number of pages11
JournalChemotherapy
Volume42
Issue numberSUPPL. 4
Publication statusPublished - 1994

Fingerprint

biapenem
Imipenem
Infection
Moxalactam
Cefoperazone
Carbapenems
Ceftazidime
Drug and Narcotic Control
Urinary Tract Infections
Clinical Studies

ASJC Scopus subject areas

  • Pharmacology

Cite this

Watanabe, T., Takenaka, T., Hayashi, T., Hata, K., Ono, N., Kumon, H., ... Jousen, T. (1994). Basic and clinical studies on biapenem in genito-urinary infections. Chemotherapy, 42(SUPPL. 4), 486-496.

Basic and clinical studies on biapenem in genito-urinary infections. / Watanabe, Toyohiko; Takenaka, T.; Hayashi, T.; Hata, K.; Ono, N.; Kumon, H.; Ohmori, H.; Kinugawa, K.; Tanaka, H.; Takada, M.; Nanba, K.; Takeda, K.; Asahi, T.; Uno, S.; Jousen, T.

In: Chemotherapy, Vol. 42, No. SUPPL. 4, 1994, p. 486-496.

Research output: Contribution to journalArticle

Watanabe, T, Takenaka, T, Hayashi, T, Hata, K, Ono, N, Kumon, H, Ohmori, H, Kinugawa, K, Tanaka, H, Takada, M, Nanba, K, Takeda, K, Asahi, T, Uno, S & Jousen, T 1994, 'Basic and clinical studies on biapenem in genito-urinary infections', Chemotherapy, vol. 42, no. SUPPL. 4, pp. 486-496.
Watanabe T, Takenaka T, Hayashi T, Hata K, Ono N, Kumon H et al. Basic and clinical studies on biapenem in genito-urinary infections. Chemotherapy. 1994;42(SUPPL. 4):486-496.
Watanabe, Toyohiko ; Takenaka, T. ; Hayashi, T. ; Hata, K. ; Ono, N. ; Kumon, H. ; Ohmori, H. ; Kinugawa, K. ; Tanaka, H. ; Takada, M. ; Nanba, K. ; Takeda, K. ; Asahi, T. ; Uno, S. ; Jousen, T. / Basic and clinical studies on biapenem in genito-urinary infections. In: Chemotherapy. 1994 ; Vol. 42, No. SUPPL. 4. pp. 486-496.
@article{d6a3b1047b6749f0b8749c1d2d9ab70f,
title = "Basic and clinical studies on biapenem in genito-urinary infections",
abstract = "We studied the antibacterial activity and clinical efficacy of biapenem (BIPM), a new carbapenem antibiotic, in the genito-urinary infections. 1) Antibacterial activity: We measured the MICs of BIPM against clinical isolates (210 strains of 14 species) from urinary tract infections, and compared them with those of imipenem (IPM), ceftazidime (CAZ), latamoxef (LMOX)and cefoperazone (CPZ). In general, antibacterial activities of BIPM were almost equal to those of IPM, but superior to those of other control drugs. 2) Clinical efficacy: According to the criteria of Japanese UTI committee, the overall clinical efficacy rate was 73.9{\%} (17/23) for chronic complicated UTI. Bacteriologically, 30 of 35 strains (85.7{\%}) were eradicated. 3) Side effect: Clinical side effects and abnormal laboratory changes were not observed in any cases.",
author = "Toyohiko Watanabe and T. Takenaka and T. Hayashi and K. Hata and N. Ono and H. Kumon and H. Ohmori and K. Kinugawa and H. Tanaka and M. Takada and K. Nanba and K. Takeda and T. Asahi and S. Uno and T. Jousen",
year = "1994",
language = "English",
volume = "42",
pages = "486--496",
journal = "Chemotherapy",
issn = "0009-3165",
publisher = "S. Karger AG",
number = "SUPPL. 4",

}

TY - JOUR

T1 - Basic and clinical studies on biapenem in genito-urinary infections

AU - Watanabe, Toyohiko

AU - Takenaka, T.

AU - Hayashi, T.

AU - Hata, K.

AU - Ono, N.

AU - Kumon, H.

AU - Ohmori, H.

AU - Kinugawa, K.

AU - Tanaka, H.

AU - Takada, M.

AU - Nanba, K.

AU - Takeda, K.

AU - Asahi, T.

AU - Uno, S.

AU - Jousen, T.

PY - 1994

Y1 - 1994

N2 - We studied the antibacterial activity and clinical efficacy of biapenem (BIPM), a new carbapenem antibiotic, in the genito-urinary infections. 1) Antibacterial activity: We measured the MICs of BIPM against clinical isolates (210 strains of 14 species) from urinary tract infections, and compared them with those of imipenem (IPM), ceftazidime (CAZ), latamoxef (LMOX)and cefoperazone (CPZ). In general, antibacterial activities of BIPM were almost equal to those of IPM, but superior to those of other control drugs. 2) Clinical efficacy: According to the criteria of Japanese UTI committee, the overall clinical efficacy rate was 73.9% (17/23) for chronic complicated UTI. Bacteriologically, 30 of 35 strains (85.7%) were eradicated. 3) Side effect: Clinical side effects and abnormal laboratory changes were not observed in any cases.

AB - We studied the antibacterial activity and clinical efficacy of biapenem (BIPM), a new carbapenem antibiotic, in the genito-urinary infections. 1) Antibacterial activity: We measured the MICs of BIPM against clinical isolates (210 strains of 14 species) from urinary tract infections, and compared them with those of imipenem (IPM), ceftazidime (CAZ), latamoxef (LMOX)and cefoperazone (CPZ). In general, antibacterial activities of BIPM were almost equal to those of IPM, but superior to those of other control drugs. 2) Clinical efficacy: According to the criteria of Japanese UTI committee, the overall clinical efficacy rate was 73.9% (17/23) for chronic complicated UTI. Bacteriologically, 30 of 35 strains (85.7%) were eradicated. 3) Side effect: Clinical side effects and abnormal laboratory changes were not observed in any cases.

UR - http://www.scopus.com/inward/record.url?scp=0028564693&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028564693&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:0028564693

VL - 42

SP - 486

EP - 496

JO - Chemotherapy

JF - Chemotherapy

SN - 0009-3165

IS - SUPPL. 4

ER -